A service improvement project to review prescribing information provided by general practitioners for new referrals to a UK National Health Service hospital pain clinic: potential implications of CYP2D6 enzyme inhibition

Abstract

Introduction:

Chronic pain is often managed using co-prescription of analgesics and adjuvants, with concomitant medication prescribed for comorbidities. Patients may have suboptimal response to some analgesics or be at risk of drug interactions or adverse drug reactions (ADRs) due to polypharmacy affecting CYP2D6 enzyme activity. The aim of the service improvement project was to determine the proportion of patients referred to a specialist pain service in the UK National Health Service (NHS) by general practitioners (GPs) who may be at risk of suboptimal analgesic response or ADRs due to CYP2D6 inhibition through polypharmacy. This was achieved by reviewing clinical prescribing information provided by GPs at time of referral. It was hoped that the findings could be used to aid clinical and prescribing decisions without conducting CYP2D6 genotyping or phenotyping.

Methods:

A review of letters from 250 patients referred to an NHS hospital pain service from GPs over a 3-month period was undertaken. Information about current and concomitant medications was analysed to identify the potential for CYP2D6 inhibition and adverse events.

Results:

Letters failed to provide information about current pain medication for 20 (8%) patients or non-pain concomitant medication for 54 (21.6%) patients. Of 176 patients, 52 (29.5%) patients with information about non-pain concomitant medication had been prescribed at least one known CYP2D6 inhibitor. A total of 35 (19.9%) patients were identified as being at risk of an adverse drug reaction and 33 (18.75%) patients at risk of suboptimal analgesic response due to co-administration of CYP2D6 inhibitors.

Conclusion:

The review revealed the need for improved detail in GP referral letters used to transfer care to UK NHS hospital pain clinics. There is a need to consider an individual’s CYP2D6 phenotype when prescribing analgesic prodrugs to manage persistent pain. Caution is needed when patients are co-prescribed codeine or tramadol with selective serotonin reuptake inhibitors (SSRIs).

Keywords

Pain management analgesic drugs general practitioner CYP2D6 polypharmacy

Get full access to this article

View all access options for this article.

References

Elzahaf

Tashani

Unsworth

. The prevalence of chronic pain with an analysis of countries with a Human Development Index less than 0.9: a systematic review without meta-analysis. Curr Med Res Opin 2012; 28(7): 1221–1229.

Bras

Loncar

Fingler

. The relief of pain as a human right. Psychiatr Danub 2006; 18(1–2): 108–110.

Breivik

Collett

Ventafridda

. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10(4): 287–333.

Fine

. Long-term consequences of chronic pain: mounting evidence for pain as a neurological disease and parallels with other chronic disease states. Pain Med 2011; 12(7): 996–1004.

Smith

. Opioid metabolism. Mayo Clin Proc 2009; 84(7): 613–624.

Singh

. Pharmacogenomics-the potential of genetically guided prescribing. Aust Fam Physician 2007; 36(10): 820–824.

Dysvik

Natvig

Eikeland

. Coping with chronic pain. Int J Nurs Stud 2005; 42(3): 297–305.

Jensen

Turner

Romano

. Coping with chronic pain: a critical review of the literature. Pain 1991; 47(3): 249–283.

Health & Social Care Information (HSCI). GP workload survey report. London: HSCIC, 2007, http://www.hscic.gov.uk/article/2021/Website-search?productid=713&;q=GP+workload+survey&sort=Relevance&size=10&page=1&area=both#top (accessed 13 October 2013).

10.

CYP2D6 allele nomenclature , 2013, http://www.cypalleles.ki.se/cyp2d6.htm (accessed 18 October 2013).

11.

Borges

Desta

Jin

. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharm 2010; 50(4): 450–458.

12.

Tirkkonen

Laine

. Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharm Ther 2004; 76(6): 639–647.

13.

British National Formulary (BNF), http://www.bnf.org/bnf/index.htm (accessed 31 January 2013).

14.

British Pain Society (BPS). Opioids for persistent pain: good practice, London: BPS 2010, https://www.britishpainsociety.org/static/uploads/resources/files/book_opioids_recommendations_short.pdf (accessed 31 June 2013).

15.

PharmaGKB. CYP2D6 dosing guidelines, http://www.pharmgkb.org/gene/PA128 (assessed 26 September 2013).

16.

Hicks

Swen

Thorn

. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharm Ther 2013; 93(5): 402–408.

17.

Swen

Nijenhuis

de Boer

. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharm Ther 2011; 89(5): 662–673.

18.

Crews

Gaedigk

Dunnenberger

. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharm Ther 2014; 95(4): 376–382.

19.

Food & Drug Administration (FDA). CYP2D6 inhibitors. Silver Spring, MD: FDA, (last updated 2011), http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#4 (accessed 4 February 2013).

20.

Medicines and Healthcare products Regulatory Agency (MHRA) UK Public Assessment Report. Tamoxifen: reduced effectiveness when used with CYP2D6 inhibitors. London: MHRA, 2011, http://www.mhra.gov.uk/home/groups/s-par/documents/websiteresources/con129101.pdf (accessed 18 October 2013).

21.

Flockhart

. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine, 2007, http://medicine.iupui.edu/clinpharm/ddis/clinical-table/ (accessed 4 February 2013).

22.

Baxter

. Stockley’s drug interactions: a source book of interactions, their mechanisms, clinical importance, and management. London: Pharmaceutical Press, 2008, p. 6.

23.

Food & Drug Administration (FDA). Aripiprazole pharmacogenomic information. Silver Spring, MD: FDA, http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm236063.htm (accessed 21 February 2014).

24.

Neafsey

Ginsberg

Hattis

. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 2009; 12(5–6): 334–361.

25.

Bradford

. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3(2): 229–243.

26.

Brauch

Schroth

Goetz

. Tamoxifen use in postmenopausal breast cancer: CYP2D6 Matters. J Clin Oncol 2013; 31(2): 176–180.

27.

Lum

DWK

Perel

Hingorani

. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS One 2013; 8(10): e76648.

28.

Preissner

Kroll

Dunkel

. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010; 38: D237–D243.

29.

Frances Report, 2013, http://www.midstaffspublicinquiry.com/report (accessed 12 January 2014).

30.

Health and Social Care Information Centre (HSCIC) and Academy of Medical Royal Colleges. Standards for the clinical structure and content of patient records. London: HSCIC, 2013.

31.

Fitzgerald

. Medication errors: the importance of an accurate drug history. Brit J Clin Pharm 2009; 67(6): 671–675.

32.

Brennan

. The clinical implications of Cytochrome P450 interactions with opioids and strategies for pain management. J Pain Symptom Manage 2012; 44(6): S15–S22.

33.

McCance-Katz

Sullivan

Nallani

. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010; 19(1): 4–16.

34.

Bertilsson

Dahl

MLL

Dalén

. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Brit J Clin Pharm 2002; 53(2): 111–122.

35.

Meyer

. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356(9242): 1667–1671.

36.

National Patient Safety Agency. Safety in doses (NPSA): medication safety incidents in the NHS. London: The Stationery Office, 2007.